SAT363 The Prevalence And Phenotype Of Polycystic Ovary Syndrome (PCOS) In A Community-Based Population In Sub-Sahara Africa: The Nigeria-PEP Study

Disclosure: C.C. Makwe: None. J.A. Olamijulo: None. M.R. Balogun: None. A.O. Akinkugbe: None. A. Samuel: None. K. Udenze: None. F. Bril: None. R.P. Buyalos: None. J.S. Laven: None. R. Azziz: Advisory Board Member; Self; Arora Forge. Consulting Fee; Self; Rani Therapeutics, Spruce Biosciences, Fortress Biotech, Core Access Surgical Technologies. Grant Recipient; Self; Ferring Pharmaceuticals. Stock Owner; Self; Martin Imaging. Background: Epidemiologic studies of unselected (medically unbiased) populations in many nations indicates that PCOS is clinically evident in 5%-15% of all reproductive-aged women. However, no systematic studies of PCOS have been performed in Sub-Sahara Africa, limiting the ability to develop rational screening and public health approaches to address the disorder in this part of the world. To address this deficit, we established the ‘PCOS Epidemiology and Phenotype in Nigeria (Nigeria-PEP)’ study. Objective: To determine the prevalence and phenotype of PCOS in an unselected population in Nigeria. Materials and methods: Women 18-45 yrs. were selected using multi-stage sampling from the Mushin and Surulere Local Government Areas of Lagos, Nigeria. All underwent a 75 gm, 2-hr. oral glucose tolerance test (OGTT) and a pelvic ultrasound between day 2-7 of the cycle (natural or induced with oral Dydrogesterone 10 mg/day x 5 day), or randomly for women who had a negative progesterone challenge test. PCOS was defined by the Rotterdam 2003 criteria. Clinical hyperandrogenism (CH) was defined by a modified Ferriman-Gallwey score of ≥6; menstrual dysfunction (MD) as menstrual cycle lengths >35 or